文献速递妇科

局部晚期宫颈癌新辅助化疗后放化疗的II期试验

Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer.
PubMed 文献 · Gynecol Oncol · 2017-07-11

在巴西累西腓一家参考中心开展的前瞻性非随机II期试验,纳入50例局部晚期宫颈癌(Ib2-IVa)患者,先接受2周期顺铂+吉西他滨新辅助化疗,再行放化疗(50.4Gy)联合每周顺铂及近距离放疗。治疗结束时缓解率81%,新辅助化疗期间3/4级毒性20%,放化疗期间44%,1年和3年无进展生存率分别为73.4%和53.9%,总生存率分别为93.9%和71.3%。作者认为新辅助化疗未显示有意义的客观缓解率改善,但认为应在前瞻性试验中进一步探索。

要点

  • 局部晚期宫颈癌患者接受新辅助化疗后放化疗,治疗结束时缓解率为81%。
  • 3/4级毒性在新辅助化疗期间为20%,在放化疗期间为44%,晚期不良事件为20%。
  • 1年和3年无进展生存率分别为73.4%和53.9%,总生存率分别为93.9%和71.3%。

核心结论

  • 作者认为,在其手中,局部晚期宫颈癌患者的新辅助化疗未显示有意义的客观缓解率改善,但认为应在前瞻性试验中进一步探索。

研究设计与样本

  • II期、前瞻性、非随机试验,在巴西累西腓一家参考中心开展,50例局部晚期宫颈癌(Ib2-IVa)患者纳入分析。

主要发现

  • 治疗结束时缓解率为81%。
  • 3/4级毒性在新辅助化疗期间为20%,在放化疗期间为44%;晚期不良事件见于20%的患者。

关键数值与推荐

  • 新辅助化疗方案:顺铂35mg/m²和吉西他滨1000mg/m²,第1天和第8天给药,共2周期。
  • 放化疗方案:50.4Gy放疗联合每周顺铂40mg/m²,随后行近距离放疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Cervical cancer is a global public health challenge. Since 1999, platin based chemoradiation (CRT) is the standard treatment for those patients with locally advanced disease. However, this population still has a dismal prognosis and, alternatives approaches such as adjuvant chemotherapy are controversial, especially because of increased toxicity. Neoadjuvant chemotherapy (NACT) could be an option for more intensive treatment with manageable toxicity. METHODS: A phase II, prospective, non-randomized trial was conducted at a reference center in Recife, Brazil. Locally advanced cervical cancer patients (Ib2-IVa) were treated with neoadjuvant cisplatin 35mg/m2 and gemcitabine 1000mg/m2 D1 and D8, for 2cycles. Then, they received CRT (50.4Gy) with weekly cisplatin 40mg/m2 followed by brachytherapy. Response rate (RR) and toxicity were the primary endpoints. Progression-free survival (PFS) and overall survival (OS) were secondary endpoints. RESULTS: Between Sep/2013 and Oct/2015, 50 patients were initiated on NACT and CRT. RR was 81% at the end of treatment. Hematological and gastrointestinal toxicity were most common. Grade 3/4 toxicity was 20% during NACT and 44% during CRT. Late adverse events were present in 20% of patients. PFS at 1 and 3-years were 73.4% (IC 58.7-83.6) and 53.9% (IC 36.9-68.3), respectively; and, OS at 1 and 3-years were 93.9% (IC 82.4-98.0) and 71.3% (IC 53.3-83.3), respectively. CONCLUSION: In our hands NACT in locally advanced cervical cancer patients did not show a meaningful improvement in ORR. Nevertheless, we believe it should be further explored in prospective trials.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. de Azevedo CRAS, Thuler LCS, de Mello MJG, et al. Phase II trial of neoadjuvant chemotherapy followed by chemoradiation in locally advanced cervical cancer. Gynecol Oncol. 2017. PMID: 28709705. doi:10.1016/j.ygyno.2017.07.006

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。